Andrew Komjathy
CIK 1788465 · Chief Commercial Officer · last filed 2026-01-23
Andrew Komjathy is a Chief Commercial Officer who has filed 9 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing, for ATXS, was dated Jan 23, 2026. Across all open-market trades the lifetime net is +$670, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
9
$670
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Astria Therapeutics, Inc. (ATXS) Delisted | Chief Commercial Officer | 0 | $12.58 | $0 | $670 | 6 | 2026-01-23 |
| Astria Therapeutics, Inc. (CATB) Delisted | Chief Commercial Officer | — | $8.54 | — | $0 | 3 | 2021-06-02 |
Recent Filings
9 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-23 | Astria Therapeutics, Inc. (ATXS) Delisted | Disp (D) | −100 | $0 | EDGAR |
| 2025-03-25 | Astria Therapeutics, Inc. (ATXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-02-12 | Astria Therapeutics, Inc. (ATXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-06 | Astria Therapeutics, Inc. (ATXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-03 | Astria Therapeutics, Inc. (ATXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-11-23 | Astria Therapeutics, Inc. (ATXS) Delisted | Buy (P) | +100 | $670 | EDGAR |
| 2021-06-02 | Astria Therapeutics, Inc. (CATB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-14 | Astria Therapeutics, Inc. (CATB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-09-19 | Astria Therapeutics, Inc. (CATB) Delisted | Grant (A) | — | $0 | EDGAR |